Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19
Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA: JAM1), signed an agreement with Cellvera Global Holdings LLC, for the co-development of ARDS-003 as a combination product, with Qifenda 400mg (Favipiravir), a commercial-stage broad-spectrum antiviral drug.
利樂生物製藥公司。(場外交易代碼：TBPMF)(多倫多證券交易所股票代碼：TBP)(法蘭克福證券交易所股票代碼：JAM1)，與Cellvera Global Holdings LLC，適用於共同開發ARDS-003作為組合產品，與奇芬達400毫克(法維拉韋)，一個商業舞臺廣譜抗病毒藥物.
As a monotherapy, compared to placebo, ARDS-003 dose-dependently reduced signs of morbidity and mortality, including respiratory distress following SARS-CoV-2 infection in the humanized ACE2 mouse model. ARDS-003 also outperformed an antiviral drug in reducing multiple proinflammatory mediators involved in hyperinflammation and immune system dysfunction following viral infection. Other studies have also demonstrated dose-dependent inhibition of viral replication.
作為一種單一療法，與安慰劑相比，ARDS-003劑量依賴地減少了發病率和死亡率的跡象，包括人源化ACE2小鼠模型中SARS-CoV-2感染後的呼吸窘迫。ARDS-003在減少參與病毒感染後的過度炎症和免疫系統功能障礙的多種促炎介質方面也優於一種抗病毒藥物。其他研究也證明瞭對病毒複製的劑量依賴性抑制。
Cellvera owns the rights to the brand originator Favipiravir, initially developed by FujiFilm Toyama Chemical Co and approved in Japan to treat pandemic influenza. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. It targets the protein needed for the coronavirus to replicate, making it impossible for the virus to copy itself. According to the company, the broad-spectrum antiviral drug is effective against 12 families of viruses, including Coronaviruses (COVID, MERS, SARS), Filoviruses (EBOLA, MARBURG), Flaviviruses (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS, and many others.
Cellvera擁有品牌發起人Favipiravir的權利，Favipiravir最初由富士富山化學公司並在日本被批准用於治療大流行性流感。法韋拉韋是一種選擇性的病毒RNA依賴的RNA聚合酶抑制劑，對包括冠狀病毒在內的單鏈RNA病毒具有很強的抗病毒活性。它針對冠狀病毒複製所需的蛋白質，使病毒不可能複製自己。據該公司稱，這種廣譜抗病毒藥物對12個病毒家族有效，包括冠狀病毒(COVID、MERS、SARS)、絲狀病毒(埃博拉、馬爾堡)、黃病毒(寨卡病毒、西尼羅河病毒、登革熱)、狂犬病、諾沃克病毒等。
As novel strains of the SARS-CoV-2 virus continue to emerge, preliminary studies on SARS-COV-2 Variants, Omicron and Delta, have shown that Favipiravir maintains its antiviral activity, demonstrating viruses' inability to resist Favipiravir even with prolonged exposure of virus-infected cells to the drug. Clinical trials of Favipiravir have shown rapid viral clearance and prevention of hospitalization when administered early in the onset of the symptoms.
隨着新的SARS-CoV-2病毒株的不斷出現，對SARS-CoV-2變種奧密克戎和Delta的初步研究表明，法比拉韋保持了其抗病毒活性，表明即使病毒感染細胞長期接觸這種藥物，病毒也無法抵抗法維拉韋。Favipiravir的臨牀試驗表明，如果在症狀出現的早期使用，病毒迅速清除並防止住院。
The parties hypothesize, based on data from AI based in-silico drug discovery platform Prepaire, that a combination product of Favipiravir and ARDS-003 has the potential to allow rapid virus clearance and provide longer-term patient benefits. ARDS-003's cytokine reduction properties may prevent some consequences of SARS-CoV-2 infection, such as severe pulmonary inflammation.
各方假設，基於基於人工智能的數據硅內藥物發現平臺 做好準備Favipiravir和ARDS-003的組合產品有可能實現病毒的快速清除，併為患者提供更長期的好處。ARDS-003的細胞因子減少特性可能預防SARS-CoV-2感染的一些後果，如嚴重的肺部炎症。
Mary O'Brien, CEO of Cellvera, stated: "The ongoing complexities of COVID-19 require multiple treatment options. By joining forces with Tetra, we hope to offer this additional treatment option to patients. This collaboration with Tetra supports our partnership strategy and the development of further combination therapies involving Qifenda. We share a passion with Tetra to deliver innovative medicines to address this pandemic. We look forward to working with Guy and his team to investigate the potential of ARDS-003 and Qfienda. By joining the Prepaire partner platform, we connect with like-minded experts from across industry, academia, and the government sector, we are better equipped to lead the way towards transforming drug discovery and development through the application of machine learning".
瑪麗·奧布萊恩Cellvera首席執行官劉強東表示：“新冠肺炎目前的複雜性要求有多種治療方案。通過與利樂的合作，我們希望為患者提供這種額外的治療選擇。與利樂的合作支持了我們的夥伴關係戰略和涉及奇芬達的進一步聯合療法的開發。我們與利樂有着共同的熱情，即提供創新的藥物來應對這一流行病。我們期待着與蓋伊和他的團隊合作，調查ARDS-003和Qfienda的潛力。通過加入Prepreire合作伙伴平臺，我們與來自工業界、學術界和政府部門的志同道合的專家建立了聯繫，我們更有能力通過應用機器學習來引領藥物發現和開發的變革。
Photo: Benzinga; Sources: courtesy of geralt, lindsayfox via Pixabay
圖片來源：Geralt，lindsayfox通過pixabay提供
Related News
相關新聞
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition
臨牀前試驗結果證實靶向2型大麻素受體有助於緩解膿毒症相關疾病
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
阿坎達將向利樂生物製藥公司提供大麻，用於FDA的癌症止痛藥試驗
Tetra Bio-Pharma Opens New Subsidiary In Australia And Provides Regulatory Update
利樂生物製藥公司在澳大利亞開設新子公司並提供最新監管信息
譯文內容由第三人軟體翻譯。